Photonis
MARCO ISLAND, FL / ACCESSWIRE / July 30, 2024 / Photonis, part of Exosens, a leading global provider of neutron and gamma detectors for the nuclear industry, announces its participation at the American Nuclear Society's Utility Working Conference and Vendor Technology Expo from August 4-7, 2024, in Marco Island, Florida. This event marks Photonis' strategic initiative to expand its presence in the U.S. market, showcasing its commitment to delivering high-quality, customized solutions tailored to the unique needs of the nuclear industry.
To view this piece of content from cdn.nwe.io, please give your consent at the top of this page.With over 50 years of experience designing and manufacturing nuclear instrumentation for French nuclear power plants and research programs, Photonis brings a wealth of expertise to the American market. The company's comprehensive catalog of nuclear components includes market-leading technology such as High-Temperature In-Core and Ex-Core Fission Chambers, Miniature Gamma Ionization Chambers, and High-Sensitivity Boron-Lined Proportional Counters. Also featured are Mineral Insulated Cable Extensions and Connectors, highlighting Photonis' capability in product development and adaptation.
This extensive experience and innovative product range have earned Photonis a reputation as a trusted partner in the nuclear industry, with customers relying on its nuclear instrumentation in over 180 nuclear power plants worldwide. Additionally, Photonis is a critical component supplier for the French Alternative Energies and Atomic Energy Commission (CEA), further solidifying its reputation as a leading provider of high-quality nuclear detection solutions.
Photonis' neutron and gamma detectors play a crucial role in ensuring safety and control of nuclear reactors, fuel reprocessing plants, radioactive waste storage, and nuclear research facilities worldwide. By expanding its presence in the U.S. market, Photonis aims to establish itself as a trusted partner capable of delivering high-quality, tailored solutions that meet the evolving needs of industry stakeholders.
"We are thrilled to participate in the ANS Utility Working Conference and introduce our advanced nuclear instrumentation solutions to the U.S. market. Photonis is dedicated to meeting the stringent safety and regulatory requirements of the nuclear industry and to becoming one of the major solutions providers in the North American market. We look forward to engaging with U.S. customers and demonstrating how our technologies can enhance the safety and efficiency of their operations," said Ulrich Laupper, President and Executive General Manager of the Ultimate Detection Business Unit of Exosens.
The company's commitment to excellence is underscored by its dedicated Research and Development team, operating under ISO9001, ISO19443, RCCE (EDF Rules), ASME NQA-1, and HAF604 certifications, ensuring rigorous quality standards across all operations.
Attendees of the ANS Utility Working Conference are invited to visit Photonis at booth #105 to explore its wide range of innovative nuclear instrumentation solutions and discuss partnership opportunities.
ABOUT PHOTONIS:
Photonis is a leading product brand of Exosens, a high-tech company with more than 85 years of experience in the innovation, development, manufacture and sale of high-end electro-optical technologies. Photonis offers its customers photo-detection and low-light conditions imaging solutions for extremely demanding environments such as Defense & Security, Nuclear Safety, Life Science and Industrial & Non-Destructive testing. Photonis is internationally recognized as a leading brand and a major innovator in its fields with production and R&D sites in Europe and North America.
For more information: exosens.com.
Contact Information:
Sales Manager
Nuclear Instrumentation Sales Manager - North America
nuclearsales@exosens.com
508-744-8769
SOURCE: Photonis Scientific, Inc.
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
GA-ASI Completes Full-Scale Fatigue Test on MQ-9B17.11.2025 03:10:00 CET | Press release
MQ-9B's Third Lifetime Test Completes the FSF Testing Process With a Total of 120,000 Hours DUBAI, UAE / ACCESS Newswire / November 16, 2025 / On October 31, 2025, General Atomics Aeronautical Systems, Inc. (GA-ASI) completed its "third lifetime" of full-scale fatigue (FSF) testing for the MQ-9B Remotely Piloted Aircraft (RPA). Completion of FSF testing for the third and final lifetime includes a total of 120,000 operating hours (40,000+ flight hours per aircraft life) for the RPA and is a key milestone in validating the design of the airframe. The testing verifies the airframe structural integrity in support of certification to the NATO STANAG 4671 standard. The aim of the testing is to identify any potential structural deficiencies ahead of fleet usage and assist in developing inspection and maintenance schedules for the airframe. Test results will be used as documentation for certification and will form the basis for in-service inspections of structural components. "The completion o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom